Related Experiment Video
Updated: May 15, 2026
12:09
Network Analysis of the Default Mode Network Using Functional Connectivity MRI in Temporal Lobe Epilepsy
Published on: August 5, 2014
Reduced default mode network connectivity in treatment-resistant idiopathic generalized epilepsy
Benjamin P Kay1, Mark W DiFrancesco, Michael D Privitera
1Neuroscience Graduate Program, University of Cincinnati, Cincinnati, Ohio, USA. benjamin@benkay.net
Epilepsia
|January 9, 2013
Summary
Reduced default mode network (DMN) connectivity is observed in idiopathic generalized epilepsy (IGE), particularly in treatment-resistant cases. This DMN connectivity may serve as a biomarker for epilepsy treatment resistance.
Area of Science:
- Neuroscience
- Epileptology
- Medical Imaging
Background:
- Idiopathic generalized epilepsy (IGE) poses a significant challenge, especially when resistant to treatment.
- The underlying neuronal mechanisms of treatment-resistant IGE remain incompletely understood.
- The default mode network (DMN) plays a crucial role in intrinsic brain function.
Purpose of the Study:
- To investigate resting-state DMN functional connectivity in patients with treatment-resistant IGE.
- To compare DMN connectivity between treatment-resistant IGE, treatment-responsive IGE, and healthy controls.
Main Methods:
- Simultaneous electroencephalography (EEG) and resting-state functional magnetic resonance imaging (fMRI) were acquired from 60 epilepsy patients and 38 healthy controls.
- Independent component analysis (ICA) and dual regression were employed to assess DMN connectivity.
- Seed-based voxel correlation analysis was used for confirmatory purposes.
Main Results:
- Patients with treatment-resistant IGE exhibited significantly reduced DMN functional connectivity compared to both treatment-responsive epilepsy patients and healthy controls.
- A negative correlation was found between DMN connectivity and the duration of epilepsy.
- These findings highlight alterations in brain network function associated with treatment resistance.
Conclusions:
- Reduced DMN connectivity is a characteristic feature of IGE.
- This reduction is more pronounced in treatment-resistant IGE.
- DMN connectivity shows potential as a biomarker for predicting or identifying treatment resistance in IGE.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...